| 743 | Humans (MeSH) |
| 389 | France (epidemiology) |
| 383 | France (MeSH) |
| 374 | Female (MeSH) |
| 359 | Influenza, Human (epidemiology) |
| 350 | Male (MeSH) |
| 322 | Adult (MeSH) |
| 283 | Middle Aged (MeSH) |
| 252 | Aged (MeSH) |
| 247 | Influenza, Human (prevention & control) |
| 203 | Adolescent (MeSH) |
| 189 | Child (MeSH) |
| 157 | Young Adult (MeSH) |
| 149 | Child, Preschool (MeSH) |
| 137 | Seasons (MeSH) |
| 133 | Infant (MeSH) |
| 120 | Influenza Vaccines (administration & dosage) |
| 110 | Aged, 80 and over (MeSH) |
| 101 | Disease Outbreaks (MeSH) |
| 100 | Influenza, Human (virology) |
| 88 | Vaccination (statistics & numerical data) |
| 88 | Animals (MeSH) |
| 79 | Risk Factors (MeSH) |
| 79 | Influenza A Virus, H1N1 Subtype (MeSH) |
| 74 | Infant, Newborn (MeSH) |
| 68 | Influenza, Human (diagnosis) |
| 65 | Incidence (MeSH) |
| 64 | Prospective Studies (MeSH) |
| 57 | Population Surveillance (MeSH) |
| 56 | Surveys and Questionnaires (MeSH) |
| 56 | Cross-Sectional Studies (MeSH) |
| 54 | Retrospective Studies (MeSH) |
| 54 | Pandemics (MeSH) |
| 54 | Influenza Vaccines (MeSH) |
| 53 | Time Factors (MeSH) |
| 51 | Disease Outbreaks (prevention & control) |
| 49 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 49 | Influenza A Virus, H1N1 Subtype (immunology) |
| 47 | Respiratory Tract Infections (epidemiology) |
| 47 | Age Factors (MeSH) |
| 45 | Influenza, Human (transmission) |
| 43 | Vaccination (MeSH) |
| 42 | Pregnancy (MeSH) |
| 40 | Influenza, Human (drug therapy) |
| 40 | Influenza Vaccines (therapeutic use) |
| 39 | Influenza, Human (complications) |
| 38 | Influenza, Human (immunology) |
| 38 | Influenza Vaccines (immunology) |
| 36 | Influenza A virus (isolation & purification) |
| 36 | Health Knowledge, Attitudes, Practice (MeSH) |
| 35 | Influenza, Human (mortality) |
| 34 | Respiratory Tract Infections (virology) |
| 34 | Attitude of Health Personnel (MeSH) |
| 33 | Cohort Studies (MeSH) |
| 32 | Antiviral Agents (therapeutic use) |
| 31 | Treatment Outcome (MeSH) |
| 29 | Sentinel Surveillance (MeSH) |
| 29 | Population Surveillance (methods) |
| 29 | Influenza Vaccines (adverse effects) |
| 28 | Vaccination (psychology) |
| 28 | Disease Outbreaks (statistics & numerical data) |
| 27 | Influenza in Birds (epidemiology) |
| 25 | Phylogeny (MeSH) |
| 24 | Pandemics (prevention & control) |
| 24 | Influenza A Virus, H1N1 Subtype (genetics) |
| 24 | Hospitalization (statistics & numerical data) |
| 23 | Orthomyxoviridae Infections (veterinary) |
| 23 | Models, Statistical (MeSH) |
| 22 | Severity of Illness Index (MeSH) |
| 21 | Prevalence (MeSH) |
| 21 | Antibodies, Viral (blood) |
| 20 | Influenza, Human (economics) |
| 20 | Age Distribution (MeSH) |
| 19 | Sensitivity and Specificity (MeSH) |
| 19 | Oseltamivir (therapeutic use) |
| 19 | Orthomyxoviridae Infections (epidemiology) |
| 19 | Influenza, Human (therapy) |
| 19 | Influenza, Human (history) |
| 19 | History, 20th Century (MeSH) |
| 19 | Anti-Bacterial Agents (therapeutic use) |
| 18 | Public Health (MeSH) |
| 18 | Paris (MeSH) |
| 18 | Birds (MeSH) |
| 18 | Attitude to Health (MeSH) |
| 17 | Virus Diseases (epidemiology) |
| 17 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 17 | Influenza in Birds (virology) |
| 17 | Hospitalization (MeSH) |
| 17 | Hemagglutination Inhibition Tests (MeSH) |
| 17 | Disease Outbreaks (veterinary) |
| 16 | Travel (MeSH) |
| 16 | Risk Assessment (MeSH) |
| 16 | Paris (epidemiology) |
| 16 | Influenza B virus (isolation & purification) |
| 16 | Influenza A virus (immunology) |
| 16 | Emergency Service, Hospital (MeSH) |
| 16 | Cross Infection (epidemiology) |
| 15 | Patient Acceptance of Health Care (MeSH) |
| 15 | Logistic Models (MeSH) |
| 15 | Influenza A virus (genetics) |
| 15 | Follow-Up Studies (MeSH) |
| 14 | Multivariate Analysis (MeSH) |
| 14 | Influenza A virus (MeSH) |
| 14 | Hospitals, University (MeSH) |
| 14 | Health Personnel (MeSH) |
| 14 | Epidemics (MeSH) |
| 14 | Case-Control Studies (MeSH) |
| 13 | United Kingdom (epidemiology) |
| 13 | Respiratory Tract Infections (diagnosis) |
| 13 | Orthomyxoviridae (isolation & purification) |
| 13 | Comorbidity (MeSH) |
| 12 | Viruses (isolation & purification) |
| 12 | Swine (MeSH) |
| 12 | Socioeconomic Factors (MeSH) |
| 12 | Sequence Analysis, DNA (MeSH) |
| 12 | Regression Analysis (MeSH) |
| 12 | Influenza A virus (classification) |
| 12 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
| 12 | Immunization Schedule (MeSH) |
| 12 | Communicable Diseases (epidemiology) |
| 11 | Vaccination (methods) |
| 11 | Risk (MeSH) |
| 11 | Pneumonia, Viral (epidemiology) |
| 11 | Patient Acceptance of Health Care (statistics & numerical data) |
| 11 | Odds Ratio (MeSH) |
| 11 | Nasopharynx (virology) |
| 11 | Molecular Sequence Data (MeSH) |
| 11 | Influenza, Human (pathology) |
| 11 | Influenza Vaccines (economics) |
| 11 | Influenza B virus (genetics) |
| 11 | Influenza A Virus, H5N1 Subtype (MeSH) |
| 11 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
| 11 | Health Policy (MeSH) |
| 11 | Health Personnel (statistics & numerical data) |
| 11 | Health Care Surveys (MeSH) |
| 11 | Epidemiological Monitoring (MeSH) |
| 10 | Vaccination (adverse effects) |
| 10 | Reproducibility of Results (MeSH) |
| 10 | Pregnancy Complications, Infectious (prevention & control) |
| 10 | Polymerase Chain Reaction (MeSH) |
| 10 | Pneumococcal Vaccines (administration & dosage) |
| 10 | Interviews as Topic (MeSH) |
| 10 | Internet (MeSH) |
| 10 | Influenza, Human (MeSH) |
| 10 | Influenza in Birds (transmission) |
| 10 | Influenza A virus (pathogenicity) |
| 10 | Influenza A Virus, H3N2 Subtype (genetics) |
| 10 | Influenza A Virus, H3N2 Subtype (MeSH) |
| 10 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 10 | Immunization Programs (MeSH) |
| 10 | Horses (MeSH) |
| 10 | Health Surveys (MeSH) |
| 10 | Global Health (MeSH) |
| 10 | Cross Infection (prevention & control) |
| 10 | Cost of Illness (MeSH) |
| 10 | Algorithms (MeSH) |
| 10 | Air Pollution (adverse effects) |
| 9 | United States (epidemiology) |
| 9 | United Kingdom (MeSH) |
| 9 | Swine Diseases (epidemiology) |
| 9 | Sex Factors (MeSH) |
| 9 | Seroepidemiologic Studies (MeSH) |
| 9 | Respiratory Syncytial Virus Infections (epidemiology) |
| 9 | RNA, Viral (genetics) |
| 9 | Practice Patterns, Physicians' (statistics & numerical data) |
| 9 | Practice Guidelines as Topic (MeSH) |
| 9 | Orthomyxoviridae Infections (virology) |
| 9 | Nursing Homes (MeSH) |
| 9 | Models, Theoretical (MeSH) |
| 9 | Longitudinal Studies (MeSH) |
| 9 | Influenza B virus (MeSH) |
| 9 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 9 | Geography (MeSH) |
| 9 | General Practice (MeSH) |
| 9 | Epidemiologic Methods (MeSH) |
| 9 | Decision Making (MeSH) |
| 9 | Coronavirus Infections (epidemiology) |
| 9 | Community-Acquired Infections (epidemiology) |
| 9 | Acute Disease (MeSH) |
| 8 | World Health Organization (MeSH) |
| 8 | Viral Proteins (genetics) |
| 8 | Vaccines (administration & dosage) |
| 8 | Urban Population (MeSH) |
| 8 | United States (MeSH) |
| 8 | Survival Analysis (MeSH) |
| 8 | Saudi Arabia (MeSH) |
| 8 | Practice Patterns, Physicians' (MeSH) |
| 8 | Orthomyxoviridae (MeSH) |
| 8 | Neuraminidase (genetics) |
| 8 | Mortality (MeSH) |
| 8 | Models, Biological (MeSH) |
| 8 | Islam (MeSH) |
| 8 | Intensive Care Units (statistics & numerical data) |
| 8 | Intensive Care Units (MeSH) |
| 8 | Influenza, Human (physiopathology) |
| 8 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
| 8 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
| 8 | Immunocompromised Host (MeSH) |
| 8 | Horse Diseases (epidemiology) |
| 8 | Homes for the Aged (MeSH) |
| 8 | History, 21st Century (MeSH) |
| 8 | Europe (MeSH) |
| 8 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 8 | Diagnosis, Differential (MeSH) |
| 8 | Data Collection (MeSH) |
| 8 | Cause of Death (MeSH) |
| 7 | Vaccination Coverage (statistics & numerical data) |
| 7 | Sex Distribution (MeSH) |
| 7 | Pregnancy Complications, Infectious (epidemiology) |
| 7 | Poisson Distribution (MeSH) |
| 7 | Pharmacovigilance (MeSH) |
| 7 | Neuraminidase (antagonists & inhibitors) |
| 7 | Motivation (MeSH) |
| 7 | Mortality (trends) |
| 7 | Military Personnel (statistics & numerical data) |
| 7 | Military Personnel (MeSH) |
| 7 | Mass Vaccination (MeSH) |
| 7 | Influenza, Human (psychology) |
| 7 | Influenza A Virus, H1N1 Subtype (physiology) |
| 7 | Health Behavior (MeSH) |
| 7 | General Practitioners (statistics & numerical data) |
| 7 | Forecasting (MeSH) |
| 7 | Feasibility Studies (MeSH) |
| 7 | Family Practice (MeSH) |
| 7 | Disease Outbreaks (history) |
| 7 | Databases, Factual (MeSH) |
| 7 | Cross Infection (virology) |
| 7 | Cost-Benefit Analysis (MeSH) |
| 7 | Computer Simulation (MeSH) |
| 7 | Air Pollutants (adverse effects) |
| 6 | Viruses (classification) |
| 6 | Virus Diseases (virology) |
| 6 | Vaccination Coverage (MeSH) |
| 6 | Vaccination (trends) |
| 6 | Statistics, Nonparametric (MeSH) |
| 6 | Space-Time Clustering (MeSH) |
| 6 | Self Report (MeSH) |
| 6 | Saudi Arabia (epidemiology) |
| 6 | Risk Assessment (methods) |
| 6 | Respiratory Tract Infections (complications) |
| 6 | Respiratory Syncytial Virus Infections (diagnosis) |
| 6 | Registries (MeSH) |
| 6 | Primary Health Care (MeSH) |
| 6 | Poultry (MeSH) |
| 6 | Pneumonia, Viral (diagnosis) |
| 6 | Pneumonia, Pneumococcal (prevention & control) |
| 6 | Pneumonia (mortality) |
| 6 | Personnel, Hospital (statistics & numerical data) |
| 6 | Personnel, Hospital (MeSH) |
| 6 | Patient Compliance (MeSH) |
| 6 | Orthomyxoviridae Infections (immunology) |
| 6 | Orthomyxoviridae (immunology) |
| 6 | Influenza, Human (blood) |
| 6 | Infection Control (methods) |
| 6 | Hospital Mortality (MeSH) |
| 6 | Health Personnel (psychology) |
| 6 | Guillain-Barre Syndrome (epidemiology) |
| 6 | Geriatrics (MeSH) |
| 6 | Genotype (MeSH) |
| 6 | General Practitioners (psychology) |
| 6 | Family Characteristics (MeSH) |
| 6 | Evolution, Molecular (MeSH) |
| 6 | Europe (epidemiology) |
| 6 | Epidemics (statistics & numerical data) |
| 6 | Emergency Service, Hospital (statistics & numerical data) |
| 6 | Drug Prescriptions (statistics & numerical data) |
| 6 | Demography (MeSH) |
| 6 | Cross Infection (transmission) |
| 6 | Confidence Intervals (MeSH) |
| 6 | Computer Systems (MeSH) |
| 6 | Communicable Disease Control (methods) |
| 6 | Chronic Disease (MeSH) |
| 6 | Antiviral Agents (administration & dosage) |
| 6 | Antibodies, Viral (analysis) |
| 6 | Antibodies, Bacterial (blood) |
| 6 | Animal Migration (MeSH) |
| 6 | Air Pollutants (analysis) |
| 5 | Vaccines, Inactivated (administration & dosage) |
| 5 | Vaccination (standards) |
| 5 | Vaccination (economics) |
| 5 | Temperature (MeSH) |
| 5 | Swine Diseases (virology) |
| 5 | Sulfur Dioxide (analysis) |
| 5 | Spatio-Temporal Analysis (MeSH) |
| 5 | Rhinovirus (isolation & purification) |
| 5 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
| 5 | Reunion (epidemiology) |
| 5 | Respiratory Tract Infections (pathology) |
| 5 | Respiratory Tract Infections (mortality) |
| 5 | Respiratory Syncytial Viruses (isolation & purification) |
| 5 | Recurrence (MeSH) |
| 5 | Real-Time Polymerase Chain Reaction (MeSH) |
| 5 | Qualitative Research (MeSH) |
| 5 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
| 5 | Pulmonary Disease, Chronic Obstructive (complications) |
| 5 | Public Opinion (MeSH) |
| 5 | Program Evaluation (MeSH) |
| 5 | Probability (MeSH) |
| 5 | Pregnancy Outcome (MeSH) |
| 5 | Pregnancy Complications, Infectious (virology) |
| 5 | Predictive Value of Tests (MeSH) |
| 5 | Poultry Diseases (virology) |
| 5 | Poultry Diseases (epidemiology) |
| 5 | Polymerase Chain Reaction (methods) |
| 5 | Pneumonia (epidemiology) |
| 5 | Pneumococcal Vaccines (therapeutic use) |
| 5 | Pneumococcal Vaccines (immunology) |
| 5 | Pneumococcal Vaccines (MeSH) |
| 5 | Pneumococcal Infections (prevention & control) |
| 5 | Pilot Projects (MeSH) |
| 5 | Physicians, Family (statistics & numerical data) |
| 5 | Pharmacists (MeSH) |
| 5 | Patient Education as Topic (MeSH) |
| 5 | Pandemics (statistics & numerical data) |
| 5 | Outcome Assessment, Health Care (MeSH) |
| 5 | Meteorological Concepts (MeSH) |
| 5 | Influenza, Human (microbiology) |
| 5 | Influenza in Birds (prevention & control) |
| 5 | Influenza Vaccines (supply & distribution) |
| 5 | Influenza Vaccines (pharmacology) |
| 5 | Influenza A Virus, H3N2 Subtype (immunology) |
| 5 | Influenza A Virus, H1N1 Subtype (classification) |
| 5 | Immunization Programs (statistics & numerical data) |
| 5 | Immunization (statistics & numerical data) |
| 5 | Hospitals, University (statistics & numerical data) |
| 5 | Health Status Indicators (MeSH) |
| 5 | Guideline Adherence (MeSH) |
| 5 | Germany (epidemiology) |
| 5 | Epidemics (prevention & control) |
| 5 | Ducks (virology) |
| 5 | Ducks (MeSH) |
| 5 | Drug Resistance, Viral (MeSH) |
| 5 | Dogs (MeSH) |
| 5 | Disease Susceptibility (MeSH) |
| 5 | Developed Countries (MeSH) |
| 5 | Coronavirus Infections (diagnosis) |
| 5 | Cluster Analysis (MeSH) |
| 5 | Asthma (epidemiology) |
| 5 | Antigens, Viral (analysis) |
| 5 | Absenteeism (MeSH) |
| 4 | Zanamivir (therapeutic use) |
| 4 | Workforce (MeSH) |
| 4 | Whooping Cough (prevention & control) |
| 4 | Weather (MeSH) |
| 4 | Warfare (MeSH) |
| 4 | Virus Diseases (pathology) |
| 4 | Virus Diseases (diagnosis) |
| 4 | Vaccines, Inactivated (immunology) |
| 4 | Vaccines, Inactivated (adverse effects) |
| 4 | Vaccines (adverse effects) |
| 4 | Urban Health (MeSH) |
| 4 | Turkeys (virology) |
| 4 | Travel (statistics & numerical data) |
| 4 | Sulfur Dioxide (adverse effects) |
| 4 | Species Specificity (MeSH) |
| 4 | Sick Leave (MeSH) |
| 4 | Schools (MeSH) |
| 4 | Respiratory Tract Infections (prevention & control) |
| 4 | Respiratory Tract Infections (microbiology) |
| 4 | Respiratory Tract Infections (drug therapy) |
| 4 | Respiratory Syncytial Virus Infections (virology) |
| 4 | Research Design (MeSH) |
| 4 | Purpura, Thrombocytopenic, Idiopathic (epidemiology) |
| 4 | Proportional Hazards Models (MeSH) |
| 4 | Primary Health Care (statistics & numerical data) |
| 4 | Population Dynamics (MeSH) |
| 4 | Pneumonia, Viral (virology) |
| 4 | Pneumonia, Pneumococcal (epidemiology) |
| 4 | Pneumococcal Infections (epidemiology) |
| 4 | Picornaviridae Infections (epidemiology) |
| 4 | Physicians, Family (MeSH) |
| 4 | Patient Acceptance of Health Care (psychology) |
| 4 | Paramyxoviridae Infections (epidemiology) |
| 4 | Oseltamivir (administration & dosage) |
| 4 | Orthomyxoviridae (genetics) |
| 4 | Occupational Health (MeSH) |
| 4 | Nitrogen Dioxide (analysis) |
| 4 | Nitrogen Dioxide (adverse effects) |
| 4 | Nasal Cavity (virology) |
| 4 | Mutation, Missense (MeSH) |
| 4 | Multiplex Polymerase Chain Reaction (MeSH) |
| 4 | Molecular Diagnostic Techniques (methods) |
| 4 | Military Medicine (MeSH) |
| 4 | Mass Vaccination (statistics & numerical data) |
| 4 | Mass Media (MeSH) |
| 4 | Length of Stay (MeSH) |
| 4 | Influenza, Human (nursing) |
| 4 | Influenza Vaccines (standards) |
| 4 | Influenza B virus (immunology) |
| 4 | Influenza A Virus, H5N2 Subtype (pathogenicity) |
| 4 | Influenza A Virus, H5N2 Subtype (isolation & purification) |
| 4 | Influenza A Virus, H3N2 Subtype (classification) |
| 4 | Infection Control (MeSH) |
| 4 | Immunosuppressive Agents (therapeutic use) |
| 4 | Immunization, Secondary (MeSH) |
| 4 | Hospitals (MeSH) |
| 4 | Hospital Units (statistics & numerical data) |
| 4 | Horse Diseases (virology) |
| 4 | History, Modern 1601- (MeSH) |
| 4 | History, 19th Century (MeSH) |
| 4 | Health Promotion (MeSH) |
| 4 | Health Facilities (MeSH) |
| 4 | HIV Infections (complications) |
| 4 | Guillain-Barre Syndrome (etiology) |
| 4 | Germany (MeSH) |
| 4 | General Practitioners (MeSH) |
| 4 | Fever (etiology) |
| 4 | Feces (virology) |
| 4 | European Union (MeSH) |
| 4 | Epidemiologic Studies (MeSH) |
| 4 | Environmental Exposure (MeSH) |
| 4 | Enterovirus Infections (epidemiology) |
| 4 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
| 4 | Double-Blind Method (MeSH) |
| 4 | Data Interpretation, Statistical (MeSH) |
| 4 | Coronavirus Infections (virology) |
| 4 | Community-Acquired Infections (mortality) |
| 4 | Community-Acquired Infections (diagnosis) |
| 4 | Communicable Disease Control (MeSH) |
| 4 | Coinfection (virology) |
| 4 | Coinfection (MeSH) |
| 4 | Cattle (MeSH) |
| 4 | Cardiovascular Diseases (epidemiology) |
| 4 | Betacoronavirus (MeSH) |
| 4 | Belgium (epidemiology) |
| 4 | Base Sequence (MeSH) |
| 4 | Bacterial Infections (epidemiology) |
| 4 | Antiviral Agents (pharmacology) |
| 4 | Antibody Formation (MeSH) |
| 4 | Anseriformes (virology) |
| 4 | Amino Acid Substitution (genetics) |
| 4 | Amino Acid Sequence (MeSH) |
| 4 | Air Pollutants (toxicity) |
| 4 | Adrenal Cortex Hormones (therapeutic use) |
| 3 | Zoonoses (epidemiology) |
| 3 | Zanamivir (administration & dosage) |
| 3 | Zanamivir (MeSH) |
| 3 | Viruses (genetics) |
| 3 | Virus Diseases (prevention & control) |
| 3 | Virology (methods) |
| 3 | Viral Vaccines (MeSH) |
| 3 | Vaccines (immunology) |
| 3 | Telephone (MeSH) |
| 3 | Syndrome (MeSH) |
| 3 | Symptom Assessment (MeSH) |
| 3 | Swine Diseases (immunology) |
| 3 | Stroke (etiology) |
| 3 | Stroke (epidemiology) |
| 3 | Stochastic Processes (MeSH) |
| 3 | Statistics as Topic (MeSH) |
| 3 | Spain (epidemiology) |
| 3 | Single-Blind Method (MeSH) |
| 3 | Sialic Acids (therapeutic use) |
| 3 | Sampling Studies (MeSH) |
| 3 | Rubella (prevention & control) |
| 3 | Reverse Transcriptase Polymerase Chain Reaction (veterinary) |
| 3 | Respirovirus Infections (epidemiology) |
| 3 | Respiratory Tract Infections (physiopathology) |
| 3 | Respiratory Distress Syndrome, Adult (therapy) |
| 3 | Respiratory Distress Syndrome, Adult (mortality) |
| 3 | Respiratory Distress Syndrome, Adult (etiology) |
| 3 | Refusal to Participate (MeSH) |
| 3 | Recombination, Genetic (MeSH) |
| 3 | Reagent Kits, Diagnostic (MeSH) |
| 3 | RNA, Viral (analysis) |
| 3 | Quality of Life (MeSH) |
| 3 | Public Policy (MeSH) |
| 3 | Public Health Surveillance (methods) |
| 3 | Public Health (statistics & numerical data) |
| 3 | Preventive Medicine (MeSH) |
| 3 | Pregnant Women (MeSH) |
| 3 | Poultry (virology) |
| 3 | Population (MeSH) |
| 3 | Policy Making (MeSH) |
| 3 | Point-of-Care Systems (MeSH) |
| 3 | Pneumonia, Viral (transmission) |
| 3 | Pneumonia, Viral (mortality) |
| 3 | Pneumonia (MeSH) |
| 3 | Plague (history) |
| 3 | Personnel, Hospital (psychology) |
| 3 | Perception (MeSH) |
| 3 | Pediatrics (MeSH) |
| 3 | Patient Satisfaction (MeSH) |
| 3 | Patient Safety (MeSH) |
| 3 | Patient Isolation (MeSH) |
| 3 | Patient Admission (statistics & numerical data) |
| 3 | Particulate Matter (toxicity) |
| 3 | Parents (psychology) |
| 3 | Ozone (toxicity) |
| 3 | Oxygen Inhalation Therapy (MeSH) |
| 3 | Oseltamivir (pharmacology) |
| 3 | Orthomyxoviridae Infections (transmission) |
| 3 | Orthomyxoviridae Infections (prevention & control) |
| 3 | Orthomyxoviridae (classification) |
| 3 | Organ Dysfunction Scores (MeSH) |
| 3 | Occupational Diseases (prevention & control) |
| 3 | Nursing Homes (statistics & numerical data) |
| 3 | Nurse's Role (MeSH) |
| 3 | Neuraminidase (immunology) |
| 3 | Netherlands (epidemiology) |
